REGISTER now for FREE 
|
FREE patent keyword monitoring and additional FREE benefits. REGISTER now for FREE
|
|
|
Drug, Bio-affecting And Body Treating Compositions > Designated Organic Active Ingredient Containing (doai) > Heterocyclic Carbon Compounds Containing A Hetero Ring Having Chalcogen (i.e., O,s,se Or Te) Or Nitrogen As The Only Ring Hetero Atoms Doai Heterocyclic Carbon Compounds Containing A Hetero Ring Having Chalcogen (i.e., O,s,se Or Te) Or Nitrogen As The Only Ring Hetero Atoms DoaiHeterocyclic Carbon Compounds Containing A Hetero Ring Having Chalcogen (i.e., O,s,se Or Te) Or Nitrogen As The Only Ring Hetero Atoms Doai patent applications listed are from June 2005 to current and include Date, Patent Application Number, Patent Title, Patent Abstract summary and are linked to the corresponding patent application page.01/25/07 - 20070021400 - Amino alcohols as therapeutic compounds in which R, R1, R2, R3, R4, R5 and R6 have the definitions illustrated in detail in the description, as beta-secretase, cathepsin D, plasmepsin II and/or HIV protease inhibitors. ... 01/25/07 - 20070021399 - Amido-amino alcohols as therapeutic compounds in which R, R1, R2, R3, R4, R5, X1 and X2 have the definitions illustrated in detail in the description, as beta-secretase, cathepsin D, plasmepsin II and/or HIV protease inhibitors. ... 01/25/07 - 20070021398 - Substituted pyrazoline compounds, their preparation and use as medicaments The present invention relates to substituted pyrazoline compounds, methods for their preparation, medicaments comprising these compounds as well as their use for the preparation of a medicament for the treatment of humans and animals. ... 01/25/07 - 20070021397 - Neurocyte protective agent A protective agent for neurons of the central nervous system and a prophylactic and/or therapeutic agent for disorders in neurons of the central nervous system is provided, each including a compound represented by donepezil hydrochloride. ... 01/04/07 - 20070004695 - Thienoisoxazolyl-and thienylpyrrazolyl phenoxy substituted propyl derivatives useful as d4 antagonists The compounds are of the class thienoisoxazolyl- and thienylpyrrazolyl-phenoxy substituted propyl derivatives, useful as D4 antagonists. Said compounds are useful for the treatment of medical conditions mediated by inhibition of D4 receptor. These conditions comprise, for example, Attention Deficit Hyperactivity Disorder, Obsessive-Compulsive Disorder, Psychoses, Substance Abuse, Substance Dependence, Parkinson's Disease, ... 12/21/06 - 20060287287 - Aminoacetamide acyl guanidines as beta-secretase inhibitors or a stereoisomer; or a pharmaceutically acceptable salt thereof, wherein R2, R3, R4, R5, R25, R26 and R27 as defined herein, their pharmaceutical compositions and methods of use. These compounds inhibit the processing of amyloid precursor protein (APP) by β-secretase and, more specifically, inhibit the production of Aβ-peptide. The present ... 12/14/06 - 20060281725 - Agents and crystals for improving excretory potency of urinary bladder Agents for improving potentcy of the urinary bladder which comprise an amine compound of non-carbamate-type having an acetylcholinesterase-inhibiting action. Particularly, crystals of a tricyclic, condensed, heterocyclic derivative are provided, which possess an excellent action to inhibit acetylcholinesterase and an action to improve the excretory potency of the urinary bladder. As ... 11/30/06 - 20060270646 - Jnk inhibitors The present invention provides novel compounds of formula (I) and their use in the inhibition of c-Jun N-terminal kinases. The present invention further provides the use of these compounds in medicine, in particular in the prevention and/or treatment of neurodegenerative disorders related to apoptosis and/or inflammation. ... 11/16/06 - 20060258633 - Amorphous tegaserod maleate Provided are amorphous and purely amorphous tegaserod maleate and processes for the preparation thereof. Also provided are pharmaceutical compositions comprising amorphous or purely amorphous tegaserod maleate and methods for the treatment of irritable bowel syndrome using the same. ... 11/09/06 - 20060252740 - Method of treating multiple myeloma using 17-aag or 17-ag or a prodrug of either in combination with a proteasome inhibitor A method for treating multiple myeloma in a subject by administering to the subject 17-allylamino-17-demethoxy-geldanamycin or 17-amino geldanamycin, or a pro drug of either 17-AAG or 17-AG, in combination with a proteasome inhibitor. ... 11/09/06 - 20060252739 - Method of treating multiple myeloma using 17-aag or 17-ag or a prodrug of either A method for treating multiple myeloma in a subject by administering 17-allylamino-17-demethoxy-geldanamycin or 17-amino geldanamycin, or a prodrug of either 17-AAG or 17-AG, to the subject. ... 11/02/06 - 20060247223 - Non-imidazole alkylamines as histamine h3- receptor ligands and their therapeutic applications W is a residue which imparts antagonistic and/or agonistic activity at histamine H3-receptors when attached to an imidazole ring in 4(5) position; R1 and R2 may be identical or different and represent each independently a lower alkyl or cycloalkyl, or taken together with the nitrogen atom to which they are ... 11/02/06 - 20060247222 - Glycosidase inhibitors and methods of synthesizing same The synthetic schemes may comprise reacting a cyclic sulfate with a 5-membered ring sugar containing a heteroatom (X). The heteroatom preferably comprises sulfur, selenium, or nitrogen. The cyclic sulfate and ring sugar reagents may be readily prepared from carbohydrate precursors, such as D-glucose, L-glucose, D-xylose and L-xylose. The target compounds ... 09/28/06 - 20060217360 - Tubulysin biosynthesis gene The invention relates to an ssDNA molecule, to a dsDNA molecule, to an RNA, to a vector, to the use thereof and to a cell, especially for the expression of tubulysin genes. ... 09/21/06 - 20060211675 - Preventives/remedies for urinary disturbance Preventives/remedies for voiding disturbance containing a compound having both of an acetylcholinesterase inhibitory action and an al antagonistic action which exhibits an excellent effect of improving the urinary function of the bladder (i.e., effects of improving urine flow rate and voiding efficiency) without affecting the urinary pressure or the blood ... 09/21/06 - 20060211674 - Combination comprising a vasculostatic compound and an alkylating agent for the treatment of a tumor The invention relates to a pharmaceutical combination which comprises (a) a vasculostatic compound, (b) an alkylating agent and (c) optionally at least one pharmaceutically acceptable carrier for simultaneous, separate or sequential use for the treatment of a tumor disease; a pharmaceutical composition comprising such a combination; the use of such ... 09/14/06 - 20060205707 - Biologically active microlides, compositions, and uses thereof The present invention further provides a comprising a therapeutically effective amount of at least one compound of the present invention, alone or in combination with at least one additional therapeutic agent. The therapeutically effect amount can be a vacuolar-type (H+)-ATPase-inhibiting effective amount and/or an anticancer effective amount. The present invention ... 09/14/06 - 20060205706 - Process for enantioselective synthesis of single enantiomers of thio-substituted arylmethanesulfinyl derivatives by asymmetric oxidation wherein Ar, Y, R1 are as defined in claim 1. ... 09/14/06 - 20060205705 - Hsp90 inhibitors, methods of making and uses therefor The invention provides purified 18,21-didehydro-18,21-dideoxo-18,21-dihydroxy-geldanamycin derivatives, pharmaceutically acceptable salts thereof and prodrugs thereof that are potent Hsp90 binding agents that are useful for the treatment and/or the amelioration of symptoms of cancer and other proliferative tissue disorders. ... 09/07/06 - 20060199791 - Anti-microbial composition comprising a metal ion chelating agent The present invention relates to compositions suitable for use as topical pharmaceutical compositions for use in the treatment or prophylaxis of a superficial microbial species infection, and/or as anti-microbial cleansing compositions for use in the sanitary cleaning of animate or inanimate surfaces. The pharmaceutical compositions comprise a physiologically acceptable metal ... 08/31/06 - 20060194777 - Compositions and methods using same for treating amyloid-associated diseases Compounds having one or more phenol moieties, derivatives thereof, compositions containing same and uses thereof for the treatment of amyloid-associated diseases are provided. ... 08/31/06 - 20060194776 - Compositions and methods for treating tissue ischemia The present invention generally provides methods for preventing or treating tissue ischemia using CXCR4 antagonists. In one embodiment, the methods include administering to a mammal a therapeutically effective amount of a particular bicylic polyamine to elevate peripheral blood EPCs. The invention has a wide spectrum of applications including reducing or ... 08/10/06 - 20060178355 - Analogs of leucascandrolide a The present invention describes leucascandrolide analogs of the formula (I), intermediates of the formula (III), pharmaceutical compositions containing the same, methods for preventing cell proliferation, and methods for treating cancers and other proliferative diseases. ... 08/03/06 - 20060172985 - Internal 1, 15-lactones of fluprostenol and related prostaglandin f2a analogs and their use in the treatment of glaucoma and intraocular hypertension Novel derivatives of prostaglandin compounds of the F-series (PGF), specifically macrocyclic internal 1,15-lactones of fluprostenol and related PGF analogs, such as cloprostenol or latanoprost. The novel analogs can be formulated into ophthalmic solutions and topically applied for the treatment of the increased intraocular pressure caused by glaucoma and the reduction ... 08/03/06 - 20060172984 - Methods and compositions of novel triazine compounds The present invention relates to methods and compositions comprising compounds that treat pathophysiological conditions arising from inflammatory responses. In particular, the present invention is directed to compounds that inhibit or block glycated protein produced induction of the signaling-associated inflammatory response in endothelial cells. The present invention relates to compounds that ... 07/27/06 - 20060166957 - Methods of treating obesity and related disorders using tellurium selenium compounds The present invention relates to methods of using tellurium and selenium containing compounds, and particularly to the use of small organic molecules containing tellurium or selenium as exemplified by the compound ammonium-trichloro(dioxoethylene-O,O′)tellurate (known by the abbreviation AS101) for treating obesity and obesity related disorders or complications and for reducing of ... 07/06/06 - 20060148777 - Anthraquinone and its derivatives There is disclosed a compound of formula (I) wherein each of X1 and X2 are independently NH-A-NR1R2, and wherein A is A C2-8 alkylene and R1 and R2 are independently selected from hydrogen, C1-4 alkyl, C2-4 hydroxy-alkyl and C2-4 aminoalkyl, or R1 and R2 together form a C2-6 alkylene group ... 07/06/06 - 20060148776 - Drug formulations having long and medium chain triglycerides Drug formulations having emulsifying agents and both medium and long chain triglycerides are described. In preferred embodiments, the long chain triglycerides negate or lessen deleterious central nervous system effects that are caused by medium chain triglycerides. ... 06/15/06 - 20060128680 - Macrocyclic module compositions Macrocyclic module compositions are made from cyclic synthons. The macrocyclic module structures are prepared by stepwise or concerted schemes which couple synthons in a closed ring. The macrocyclic module structures may have a pore of nanometer dimensions. ... 06/08/06 - 20060122163 - Processes of making and using pharmaceutical formulations of antineoplastic agents In its several embodiments, this invention discloses a pharmaceutical formulation comprising at least one antineoplastic agent or a pharmaceutically acceptable salt thereof, and at least one dissolution enhancing agent sufficient to substantially dissolve said at least one antineoplastic agent in at least one aqueous diluent, wherein said dissolution enhancing agent ... 06/08/06 - 20060122162 - Methods of using temozolomide formulation intrathecally in the treatment of cancers Methods are disclosed for treating cancer in a patient in need of such treating comprising intrathecally administering temozolomide in a pharmaceutical formulation in a therapeutically effective amount. ... 06/01/06 - 20060116361 - 5-amidino-2-hydroxybenzenesulfonamide derivatives, pharmaceutical compositions containing the same and intermediates for their preparation R2 is a di(lower alkyl)amino group, a lower alkyl group, a cycloalkyl group, an optionally substituted aryl group, an optionally substituted heterocycloalkyl group, or an optionally substituted aromatic heterocyclic group; T is an oxygen atom, a sulfur atom, a sulfonyl group etc.; Q is a hydrogen atom or an optionally ... 05/11/06 - 20060100188 - Treatment methods There are disclosed methods for treating cancer in a patient in need of such treating comprising administering temozolomide according to improved dosing regimen and/or schedules based on the patient's MGMT level. Additional improved methods for treating patients with temozolomide are also disclosed. ... 05/11/06 - 20060100187 - Synergistic combinations of macrolide t-cell modulator or immunosuppressant and a retinoid Additive or synergistic combinations of a macrolide T-cell immunomodulator or immunosuppressant such as 33-epichloro-33-desoxyascomycin and a retinoid, such as etretinate, isotretinoin or tazarotene, optionally with a further pharmaceutically active agent, especially an antibacterial, are provided, which are useful in particular in the treatment of dermatological diseases such as eczema, atopic ... 05/04/06 - 20060094702 - 5-ht4 receptor antagonists R6, R7 and R8 are independently hydrogen or C1-6 alkyl; and R9 is hydrogen or C1-10alkyl; and their use as pharmaceuticals in the treatment of gastrointestinal disorders, cardiovascular disorders and CNS disorders. ... 05/04/06 - 20060094701 - Use of beta-2 bronchodilator drugs Improved use of selective β2 sympathomimetic bronchodilator drugs in the therapy of obstructive or inflammatory airways disease, e.g. asthma, comprises use in enantiomeric rather than conventional racemic form. The improved use reduces occurrence of side effect, e.g. exacerbation of basal disease status or compromise or deterioration of lung function. ... 04/13/06 - 20060079494 - Specific kinase inhibitors Resorcylic acid lactones having a C5-C6 cis double bond and a ketone at C7 and other compounds capable of Michael adduct formation are potent and stable inhibitors of a subset of protein kinases having a specific cysteine residue in the ATP binding site. ... 04/13/06 - 20060079493 - Methods for treating genetically- defined proliferative disorders with hsp90 inhibitors The invention relates generally to methods of treating cell proliferative diseases with HSP90 inhibitors and, depending on the specific aspect and embodiment(s) claimed, to the treatment of proliferative diseases that are associated with fusion proteins, e.g., bcrabl, or mutant proteins or cellular protein isoforms, e.g., mutant forms of p53. ... 04/06/06 - 20060074062 - Substituted porphyrins The present invention relates, in general, to a method of modulating physiological and pathological processes and, in particular, to a method of modulating cellular levels of oxidants and thereby processes in which such oxidants are a participant. The invention also relates to compounds and compositions suitable for use in such ... 03/30/06 - 20060069078 - Management of ophthalmologic disorders, including macular degeneration A drug may be used in the preparation of a medicament for the treatment or prevention of an ophthalmologic disorder, wherein the drug inihibits, antagonizes, or short-circuits the visual cycle at a step of the visual cycle that occurs outside a disc of a rod photoreceptor cell. ... 03/30/06 - 20060069077 - Receptor-type kinase modulators and methods of use The present invention provides compounds for modulating receptor kinase activity, particularly ephrin and EGFR, and methods of treating diseases mediated by receptor kinase activity utilizing the compounds and pharmaceutical compositions thereof. Diseases mediated by receptor kinase activity include, but are not limited to, diseases characterized in part by abnormal levels ... 03/23/06 - 20060063750 - Use of tellurium containing compounds as nerve protecting agents A novel neuroprotective agent is disclosed for the treatment and prevention of neurodegenerative disorders which is based on the administration of an effective amount of a tellurium compound which has a specific ability to induce the differentiation and interfere with apoptotic cell death pathways of neuronal PC-12 cells. ... 03/16/06 - 20060058279 - Topical compositions comprising ascomycins The present invention relates to a composition for topical administration comprising an ascomycin and a carrier vehicle vehicle comprising means to retain water in the outer skin layer and means to hinder water evaporating from the skin. ... 03/16/06 - 20060058278 - Macrocyclic beta-secretase inhibitors for the treatment of alzheimer's disease which are inhibitors of the beta-secretase enzyme and that are useful in the treatment or prevention of diseases in which the beta-secretase enzyme in involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the ... 03/09/06 - 20060052356 - Pharmacological methods to modulate oxygen consumption Methods of modulating oxygen consumption in tissues are provided. In particular, the methods involve the administration of agents that transiently inhibit protein synthesis. The methods are used to treat ischemia and reperfusion-related injuries by temporarily decreasing oxygen consumption needs, and/or by inhibiting inflammation that results from reperfusion. ... 03/09/06 - 20060052355 - Process for preparing 3-chloromethyl-1,2,4-triazolin-5-one The present invention is directed to processes for the preparation of 3-chloromethyl-1,2,4-triazolin-5-one. This compound is useful as an intermediate in the synthesis of compounds which possess pharmacological activity. Also disclosed are novel semicarbazide salts and the preparation thereof, which are intermediates for the preparation of 3-chloromethyl-1,2,4-triazolin-5-one. ... 02/23/06 - 20060040911 - Method for preventing and/or treating the cardiovascular and hepatic diseases induced by hyperlipidemia which comprises administered an effective amount of bioflavonoids extract derived from fructus crataegus (lipid metabolism and fructus crataegus) A method for treating and/or preventing the cardiovascular and hepatic diseases induced by hyperlipidemia which comprises administered thereto an effective amount of bioflavonoids extract derived from fructus crataegus such as; rutin, quercetin, kaempferol and vitexin or a mixture thereof. ... 02/23/06 - 20060040910 - Macrocycles useful in the treatment of alzheimer's disease for treating Alzheimer's disease and other similar diseases. These compounds include inhibitors of the beta-secretase enzyme that are useful in the treatment of Alzheimer's disease and other diseases characterized by deposition of A beta peptide in a mammal. The compounds of the invention are useful in pharmaceutical compositions and methods ... 02/23/06 - 20060040909 - Selenophene compounds In formula (I), each of R1 and R2, independently, is H, C1-C10 alkyl, C3-C20 cycloalkyl, C3-C20 heterocycloalkyl, aryl, heteroaryl, or C(O)Ra; X is Se, S, O, or NRb; and each of R3, R4, R5, and R6, independently, is H, C1-C10 alkyl, C3-C20 cycloalkyl, C3-C20 heterocycloalkyl, aryl, or heteroaryl; in which ... 02/23/06 - 20060040908 - Novel chalcogenoxanthylium dyes for purging blood pathogens and for photodynamic therapy Provided are chalcogenoxanthylium compounds which can effectively be used as sensitizers in photodynamic therapy, virucides in photodynamic antimicrobial chemotherapy and reversal agents of Pgp function in cancer cells. Further provided is a general method for the preparation of chalcogenoxanthylium compounds. ... 02/23/06 - 20060040907 - Triptolide analogs for the treatment of autoimmune and inflammatory disorders The present invention provides synthetic methods and compositions for treatment of autoimmune and anti-inflammatory disorders comprising administering an effective amount of a derivative of triptolide alone or in combination or alternation with other anti-autoimmune or anti-inflammatory compounds. ... 02/23/06 - 20060040906 - Piperazine urea derivatives as melanocortin-4 receptor agonists Certain novel piperazine urea derivatives are agonists of the human melanocortin-4 receptor (MC-4R) and, in particular, are receptor-subtype selective agonists of MC-4R. They are useful for the treatment, control, or prevention of diseases and disorders responsive to the activation of MC-4R, such as obesity and diabetes. ... 02/23/06 - 20060040905 - Formulation of nefopam and its use in the treatment of pain (+)-Nefopam is formulated for intranasal administration, for use in the treatment of pain. ... 02/16/06 - 20060035879 - Organic compounds A drug delivery device or system comprising: a) a medical device, e.g. a coated stent or stent-graft, adapted for local application or administration in hollow tubes; and in conjunction therewith, b) a therapeutic dosage of an anti-inflammatory ascomycin derivative, such as pimecrolimus, e.g. affixed to the medical device, and use ... 02/16/06 - 20060035878 - Novel use of ansamycin antibiotics and method of screening novel angiogenesis inhibitor The present invention provides novel angiogenesis inhibitors effective, safe and highly practical for inhibition of angiogenesis in various diseases, and a method for screening the same. The active ingredients of the angiogenesis inhibitors of the present invention comprise ansamycin antibiotics such as rifampicin, rifamycin SV and 3-formyl rifamycin, which have ... 02/09/06 - 20060030553 - Cell adhesion inhibitors The present invention relates to novel compounds that are useful for inhibition and prevention of cell adhesion and cell adhesion-mediated pathologies. This invention also relates to pharmaceutical formulations comprising these compounds and methods of using them for inhibition and prevention of cell adhesion and cell adhesion-mediated pathologies. The compounds and ... 02/02/06 - 20060025396 - Isophthalic acid derivatives as matrix metalloproteinase inhibitors each R4 and R5 independently are H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, (CH2)n aryl, (CH2)n cycloalkyl, (CH2)n heteroaryl, or R4 and R5 when taken together with the nitrogen to which they are attached complete a 3- to 8-membered ring, optionally containing a heteroatom selected from O, S, or NH, ... 02/02/06 - 20060025395 - Analogs of dictyostatin, intermediates therefor and methods of synthesis thereof wherein R23a is H, a protecting group, an alkyl group, a benzyl group, a trityl group, —SiRaRbRc, CH2ORd, or CORe; R23b is H, a protecting group, an alkyl group, a benzyl group, a trityl group, —SiRaRbRc, CH2ORd, or CORe, or R23a and R23b together form a portion of six-membered acetal ... 01/26/06 - 20060019941 - Analogs of benzoquinone-containing ansamycins and methods of use thereof The present invention provides analogs of benzoquinone-containing ansamycins and uses thereof for treating and modulating disorders associated with hyperproliferation, such as cancer. The present invention provides analogs of benzoquinone-containing ansamycins where the benzoquinone is reduced to a hydroquinone and trapped by reaction with a suitable acid, preferably ones that increase ... 01/26/06 - 20060019940 - Novel benzoxazocines and their therapeutic use Compounds of the general formula (1), wherein one of W, X, Y and Z is N or CR4 and the others are each CH; and R4 is a specified substituent. These compounds inhibit monocamine reuptake, and are useful in the treatment of pain, emesis depression, post traumatic stress disorders, attention ... 01/26/06 - 20060019939 - Analogs of benzoquinone-containing ansamycins and methods of use thereof The present invention provides analogs of benzoquinone-containing ansamycins and uses thereof for treating and modulating disorders associated with hyperproliferation, such as cancer. The present invention provides analogs of benzoquinone-containing ansamycins where the benzoquinone is reduced to a hydroquinone and trapped by reaction with a suitable acid, preferably ones that increase ... 01/19/06 - 20060014731 - Analogs of benzoquinone-containing ansamycins and methods of use thereof The present invention provides analogs of benzoquinone-containing ansamycins and uses thereof for treating and modulating disorders associated with hyperproliferation, such as cancer. The present invention provides analogs of benzoquinone-containing ansamycins where the benzoquinone is reduced to a hydroquinone and trapped by reaction with a suitable acid, preferably ones that increase ... 01/19/06 - 20060014730 - Ansamycin formulations and methods for producing and using same Ansamycin formulations and methods of producing and using the same are described and claimed. The formulations are emulsions that can be used directly in a patient, or be lyophilized and/or frozen, to be later used, e.g., upon re- or further hydration or processing. ... 01/12/06 - 20060009441 - Human trace amine associated receptors The present invention provides a fingerprint sequence which is specific and selective for trace amine associated receptors (TAAR) forming a subfamily of G protein coupled receptors. The invention also provides the novel human polypeptides identified as members of this family, nucleic acids encoding said polypeptides, and vectors and host cells ... 01/12/06 - 20060009440 - Heterocyclic compounds and antitumor drugs containing the same as the active ingredient wherein X represents nitrogen atom or CH; R1 represents halogen atom or hydroxyl; R2 represents hydrogen atom, hydroxyl or amino; R3 represents morpholino (which may be substituted with one or two C1-C6 alkyl), pyrrolidinyl (which may be substituted with hydroxy C1-C6 alkyl) or NR6R7 [R6 represents C1-C6 alkyl and R7 ... 01/12/06 - 20060009439 - Novel physiologically active substances (wherein, R3, R6, R7 and R21 are the same as or different from one another and each represents a hydroxyl group etc.), a pharmacologically acceptable salt thereof or a hydrate of them. The compound (I) of the present invention suppresses angiogenesis, in particular, suppresses VEGF production in a hypoxic condition ... 01/05/06 - 20060003979 - Topical compositions of cyclic amides as immunotherapeutic agents Novel amides and imides are inhibitors of tumor necrosis factors and phosphodiesterase and can be used to combat cachexia, endotoxic shock, retrovirus replication, asthma, and inflammatory conditions. ... 01/05/06 - 20060003978 - Macrocycles useful in the treatment of alzheimer's disease for treating Alzheimer's disease and other similar diseases. These compounds include inhibitors of the beta-secretase enzyme for the treatment of Alzheimer's disease and other diseases characterized by deposition of A beta peptide in a mammal. The compounds of the invention are useful in pharmaceutical compositions and methods of treatment to ... 12/29/05 - 20050288269 - Analogs of benzoquinone-containing ansamycins and methods of use thereof The present invention provides analogs of benzoquinone-containing ansamycins and uses thereof for treating and modulating disorders associated with hyperproliferation, such as cancer. The present invention provides analogs of benzoquinone-containing ansamycins where the benzoquinone is reduced to a hydroquinone and trapped by reaction with a suitable acid, preferably ones that increase ... 12/01/05 - 20050267088 - Compositions for treating hyperemia The present compositions advantageously treat hyperemia with substantially no added irritation to the eye. In one embodiment, the compositions include an ophthalmically acceptable carrier component, a vasoconstrictor component in an amount effective to treat hyperemia when the composition is administered to an eye, and a polyanionic component in an amount ... 12/01/05 - 20050267087 - Inflammatory eye disease The present invention provides methods, kits and compositions for treating uveitis in a subject using Hsp90 inhibitors. ... 11/24/05 - 20050261263 - Benzoquinone ansamycins The invention relates to benzoquinone ansamycin analogs useful for the treatment of cancer and other diseases or conditions characterized by undesired cellular proliferation or hyperproliferation. Therapies involving the administration of such benzoquinone ansamycin analogs, optionally in combination with an inhibitor of an HSP90 client protein, are useful to treat cancer ... 11/24/05 - 20050261262 - Rifamycin derivatives effective against drug-resistant microbes Rifamycin derivatives having antimicrobial activities, including activities against drug-resistant microorganisms are claimed in this invention. The inventive rifamycin derivatives are uniquely designed in that they have a rifamycin moiety covalently linked to a linker group through the C-3 carbon of the rifamycin moiety and the linker is, in turn covalently ... 11/17/05 - 20050256097 - Pharmaceutical solution formulations containing 17-aag A pharmaceutical solution formulation containing 17-AAG in an amount of up to 15 mg/mL dissolved in a vehicle comprising (i) a first component that is ethanol, in an amount of between about 40 and about 60 volume %; (ii) a second component that is a polyethoxylated castor oil, in an ... 11/17/05 - 20050256096 - C-25 carbamate rifamycin derivatives with activity against drug-resistant microbes Compounds of the current invention relate to rifamycin derivatives having antimicrobial activities, including activities against drug-resistant microorganisms. More specifically, compounds of the current invention relate to C-25 carbamate derivatives of rifamycin having another functional group or pharmacophore covalently attached to this position through a carbamate linkage. The resulting compounds exert ... 11/10/05 - 20050250753 - Fused tricyclic compounds as inhibitors of 17beta-hydroxysteroid dehydrogenase 3 Fused tricyclic compounds, methods of using such compounds in the treatment of hormone sensitive diseases such as prostate cancer, and pharmaceutical compositions containing such compounds. ... 11/10/05 - 20050250752 - Cembranoids with chemopreventive activity A cembranoid compound of the following formula (I) as described herein. The compounds of the present invention are useful as chemopreventive and chemotherapeutic agents. ... 10/20/05 - 20050234031 - Amino-substituted tricyclic derivatives and methods of use wherein A and B are amine-substituted sidechains, Y1 and Y2 form various tricyclic cores, Xa and Xb are C, CH, or N, as defined herein, and Rx is an optional substituent. Compounds and compositions of formula (I) are contemplated as well as methods for treating conditions or disorders prevented by ... 10/20/05 - 20050234030 - Modulators of crth2, cox-2 and faah Certain substituted indoles that are modulators of one or more or of CRTH2, COX-2 AND FAAH are described. The compounds are useful for treatment of pain and/or inflammation as well as other disorders. ... 10/20/05 - 20050234029 - Compounds The invention relates to novel imidazopyridine derivatives which are inhibitors of the transforming growth factor, (“TGF”)-β signalling pathway, in particular, the phosphorylation of smad2 or smad3 by the TGF-β type I or activin-like kinase (“ALK”)-5 receptor, methods for their preparation and their use in medicine, specifically in the treatment and ... 10/13/05 - 20050227955 - Analogs of benzoquinone-containing ansamycins and methods of use thereof The present invention provides analogs of benzoquinone-containing ansamycins and uses thereof for treating and modulating disorders associated with hyperproliferation, such as cancer. The present invention provides analogs of benzoquinone-containing ansamycins where the benzoquinone is reduced to a hydroquinone and trapped by reaction with a suitable acid, preferably ones that increase ... 09/22/05 - 20050209210 - Rifamycin imino derivatives effective against drug-resistant microbes The present invention relates to rifamycin 3-iminomethylenyl (—CH═N—) derivatives having antimicrobial activities, including activities against drug-resistant microorganisms. The claimed rifamycin derivative has a rifamycin moiety covalently linked to a linker through an iminomethylenyl (—CH═N—) group at the C-3 carbon of the rifamycin moiety and the linker is, in turn, covalently ... 09/15/05 - 20050203077 - Selenophene anti-tumor agents H, CHO, CH2OH and CH2NH2; and X and Y are independently selected from the group consisting of Se, S, O, NCH3, and NH. Pharmaceutical compositions and a method for treating patients having tumors utilizing the disclosed selenophene compounds are also described. ... 09/15/05 - 20050203076 - Rifamycin c-11 oxime derivatives effective against drug-resistant microbes The invention relates to rifamycin derivatives having antimicrobial activities, including activities against drug-resistant microorganisms, specifically, the rifamycin derivatives having an oxime group at the C-11 position. ... 09/01/05 - 20050192265 - Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds Disclosed are compounds which inhibit β-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions that include a compound which inhibits β-amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with such ... 08/25/05 - 20050187206 - Novel crystalline forms of temozolomide Disclosed are novel crystalline forms of Temozolomide, methods of preparation thereof, medicaments including the novel crystalline forms of Temozolomide, and uses thereof in the treatment of medical conditions. ... 08/11/05 - 20050176696 - Synergistic anit-cancer compounds The present invention provides compositions useful in treating cancer. The compositions include a synergistic combination of an antineoplastic thiol-binding mitochondrial oxidant with an antineoplastic nucleic acid binding agent, an antineoplastic antimetabolite base analog, or docetaxel. Also provided are methods of assaying the synergistic effects of the combinations and methods of ... 08/11/05 - 20050176695 - Process for preparing 17-allyl amino geldanamycin (17-aag) and other ansamycins Efficient chemical processes for preparing high yields, purities, and different polymorphic forms of 17-allyl amino geldanamycin (17-AAG) and other ansamycins are described and claimed. ... 07/21/05 - 20050159400 - Manzamines in the treatment of infectious disease A method of treating an infectious disease or condition in a subject in need of such treatment is disclosed. The method comprises administering to a subject an effective amount of a manzamine, manzamine derivative or analog or an optical isomer or racemate or tautomer thereof or a pharmaceutically acceptable salt ... 07/07/05 - 20050148566 - Polydiazeniumdiolated cyclic polyamines with polyphasic nitric oxide release and related compounds, compositions comprising same and methods of using same in which at least two of R1, R2, R3, R4, R5, and R6 are N2O2M and related compounds, substrates, compositions, and methods of using such compounds and compositions to treat biological disorders in which a polyphasic release of nitric oxide would be beneficial. ... 06/23/05 - 20050137179 - Bis-aryl sulfonamides Compounds are provided that act as potent antagonists of chemokine receptors. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of chemokine receptor-mediated diseases, and as controls in assays for the identification of chemokine antagonists. ... 06/16/05 - 20050130949 - Cyclic polyamine compounds for cancer therapy where A1, each A2 (if present), and A3 are independently selected from C1-C8 alkyl, where each Y is independently selected from H or C1-C4 alkyl, where M is selected from C1-C4 alkyl, where k is 0, 2, or 3, and where R is selected from C1-C32 alkyl, as well as ... 06/09/05 - 20050124597 - Novel guanidinyl derivatives A variety of small, guanidino group-containing molecules capable of acting as MC4-R agonists are provided. The compounds have various structures provided herein. The compounds are useful in treating MC4-R mediated diseases and may be formulated into pharmaceutical formulations and compositions. ... ### FreshPatents.com Support |